Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study,Liver Cancer

当前位置： X-MOL 学术 › Liver Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
Liver Cancer ( IF 13.8 ) Pub Date : 2022-11-30 , DOI: 10.1159/000528356
Jia-Yi Wu _{1,

2} , Zhi-Bo Zhang ₃ , Jian-Yin Zhou ₄ , Jing-Peng Ke ₅ , Yan-Nan Bai _{1,

2} , Yu-Feng Chen ₆ , Jun-Yi Wu _{1,

2} , Song-Qiang Zhou _{1,

2} , Shuang-Jia Wang ₅ , Zhen-Xin Zeng ₁ , Yi-Nan Li ₁ , Fu-Nan Qiu _{1,

2} , Bin Li ₅ , Mao-Lin Yan _{1,

2}

Affiliation

Introduction. The actual rate of conversion surgery and its prognostic advantages remain unclear. This study aimed to assess the outcomes of salvage surgery after conversion therapy with triple therapy (transcatheter arterial chemoembolization (TACE) combined with lenvatinib plus anti-PD-1 antibodies) in patients with initially unresectable hepatocellular carcinoma (uHCC). Methods. Patients with initially uHCC who received at least one cycle of first-line triple therapy and salvage surgery at five major cancer centers in China were included. The primary endpoints were overall survival (OS) and recurrence-free survival (RFS) rates after salvage surgery. The secondary endpoints were perioperative complications, 90-day mortality, and pathological tumor response. Results. Between June 2018 and December 2021, 70 patients diagnosed with uHCC who underwent triple therapy and salvage surgery were analyzed: 39 with Barcelona Clinic Liver Cancer (BCLC) stage C, 22 with BCLC stage B, and 9 with BCLC stage A disease. The median interval between the start of triple therapy and salvage surgery was 4.3 months (range, 1.7–14.2 months). Pathological complete response and major pathological response were observed in 29 (41.4%) and 59 (84.3%) patients, respectively. There were two cases of perioperative mortality (4.3%) and five cases of severe perioperative complications (7.1%). With a median follow-up of 12.9 months after surgery (range, 0.3–36.8 months), the median OS and RFS were not reached. The 1- and 2-year OS rates were 97.1% and 94.4%, respectively, and the corresponding RFS rates were 68.9% and 54.4%, respectively. Conclusion. First-line combination of TACE, lenvatinib, and anti-PD-1 antibodies provides a better chance of conversion therapy in patients with initially uHCC. Furthermore, salvage surgery after conversion therapy is effective and safe and has the potential to provide excellent long-term survival benefits.

更新日期：2022-11-30

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>